Autoantibodies in SLE but not in scleroderma react with protein-stripped nucleosomes

• Published in: Journal of autoimmunity 2004-06, Vol.22 (4), p.325-334
• Main Authors: Suer, Waltraud, Dähnrich, Cornelia, Schlumberger, Wolfgang, Stöcker, Winfried
• Format: Article
• Language: English
• Subjects: Anti-nucleosome antibodies; Antibodies, Antinuclear - blood; Autoantibodies - blood; Autoantigens - isolation & purification; Biological and medical sciences; Case-Control Studies; DNA - immunology; DNA - isolation & purification; dsDNA; Enzyme-Linked Immunosorbent Assay; General aspects; Humans; Immunopathology; Lupus Erythematosus, Systemic - immunology; Medical sciences; Nuclear Proteins - immunology; Nucleosomes - immunology; Polymyositis - immunology; Progressive systemic sclerosis; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Scleroderma, Diffuse - immunology; Sjogren's Syndrome - immunology; Systemic lupus erythematosus
• ISSN: 0896-8411; 1095-9157
• DOI: 10.1016/j.jaut.2004.02.002

Autoantibodies against nucleosomes (ANuA) are known to be sensitive markers for systemic lupus erythematosus (SLE), but their clinical relevance seemed to be limited because sera from patients with progressive systemic sclerosis (PSS) also showed positive reactions with conventional ANuA ELISA test systems (anti-Nu1 ELISA). It was generally assumed thatANuA were associated with both diseases. Using discontinuous sucrose gradient centrifugation to generate pure nucleosomes, we discovered by chance that at the 30–50% sucrose interface an antigen (Nu2) banded which was demonstrably free of non-histone components and histone H1. The two different nucleosome preparations, Nu1 and Nu2, were used in parallel as antigenic substrates in standardised ELISA tests to analyse sera from SLE (295 patients), PSS (119) and patients with other rheumatic diseases (101). With Nu1, 62% of the SLE and 52% of the PSS sera showed positive reactions. Two sera from patients suffering from Sjögren's syndrome (SS) and one from polymyositis were also positive. Using the Nu2 preparation, 58% of the SLE but none of the PSS sera showed a positive reaction. One serum from a patient with SS was also positive. It could be shown that it was the PSS-specific autoantigen Scl-70 in the nucleosome preparation (Nu1) which contributed to the positive reactions of the PSS sera in conventional ANuA test systems, whereas in the Nu2 preparation no remaining Scl-70 was detectable. The present study definitely proved that ANuA are highly and specifically associated with SLE but not with PSS.